Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

89Zr-DFO*-Trastuzumab - Astrazeneca

Next Previous
Drug Profile

89Zr-DFO*-Trastuzumab - Astrazeneca

Alternative Names: 89Zr-DFO*Trastuzumab; 89Zr-labeled trastuzumab

Latest Information Update: 28 Jul 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AstraZeneca
  • Class Antineoplastics; Drug conjugates; Imaging agents; Immunoconjugates; Monoclonal antibodies; Monoclonal antibody diagnostics; Radiopharmaceutical diagnostics; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters; Radionuclide imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Breast cancer
  • No development reported Gastric cancer; HER2 positive breast cancer

Most Recent Events

  • 28 Jul 2026 No recent reports of development identified for phase-I development in Breast-cancer(Diagnosis) in Netherlands (Parenteral, Injection)
  • 28 Jul 2026 No recent reports of development identified for phase-I development in Gastric-cancer(Diagnosis) in Netherlands (Parenteral, Injection)
  • 28 Jul 2026 No recent reports of development identified for phase-I development in HER2-positive-breast-cancer(Diagnosis) in Netherlands (Parenteral, Injection)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top